Omeros Corporation (OMER) reported quarterly earnings results on Tuesday, May-10-2016. The company reported $-0.54 earnings per share for the quarter, missing the analyst consensus estimate by $-0.11. Analysts had a consensus of $-0.43. The company posted revenue of $7.40 million in the period, compared to analysts expectations of $8.56 million. The company’s revenue was up 1797.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.51 EPS.
Many Wall Street Analysts have commented on Omeros Corporation. Shares were Reiterated by Needham on Mar 2, 2016 to “Buy” and Lowered the Price Target to $ 28 from a previous price target of $30 .Shares were Reiterated by Wedbush on Feb 29, 2016 to “Outperform” and Lowered the Price Target to $ 62 from a previous price target of $65 .
Omeros Corporation opened for trading at $12.15 and hit $12.42 on the upside on Friday, eventually ending the session at $12.38, with a gain of 1.06% or 0.13 points. The heightened volatility saw the trading volume jump to 2,25,320 shares. Company has a market cap of $474 M.
In a different news, on Apr 15, 2016, Marcia S. Kelbon (VP Patent and General Counsel) sold 15,900 shares at $15.18 per share price. According to the SEC, on Nov 20, 2015, Thomas J. Cable (director) sold 2,000 shares at $13.73 per share price. On Sep 8, 2015, Peter A Md Demopulos (director) purchased 3,962 shares at $12.68 per share price, according to the Form-4 filing with the securities and exchange commission.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation coagulopathies and disorders of the central nervous system. Its marketed drug product Omidria is approved in the United States for use during cataract surgery or intraocular lens (IOL) which is replacement surgery to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omidria is derived from its PharmacoSurgery platform which is for patients undergoing ophthalmological arthroscopic urological and other surgical procedures. It also has six clinical-stage development programs in its pipeline which includes a group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor drug targets and the other used to generate antibodies.